Rituximab: all 1,386 studies that test it

Page 14 of 14. Open to participants first (177), then studies with results posted, then the rest; newest registration first within each.

• Vaccine Therapy and Sargramostim Compared With Placebo and Sargramostim Following Rituximab in Treating Patients With Non-Hodgkin's LymphomaTerminatedNCT00089115Phase 3
• Bryostatin 1 and Rituximab in Treating Patients With B-Cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic LeukemiaCompletedNCT00087425Phase 2
• Beta-Glucan and Rituximab in Treating Young Patients With Relapsed or Progressive Lymphoma or Leukemia, or Lymphoproliferative Disorder Related to Donor Stem Cell TransplantationTerminatedNCT00087009Phase 1
• Oblimersen, Rituximab and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Aggressive Non-Hodgkin's LymphomaCompletedNCT00086944Phase 1/2
• Fludarabine Combined With Either Alemtuzumab or Rituximab in Treating Patients With Refractory or Relapsed B-Cell Chronic Lymphocytic LeukemiaCompletedNCT00086775Phase 2
• Study of Talabostat and Rituximab in Advanced Chronic Lymphocytic Leukemia (CLL)CompletedNCT00086203Phase 2
• VELCADE® (Bortezomib) With Rituximab in Subjects With Relapsed or Refractory Indolent B-Cell LymphomaCompletedNCT00085696Phase 2
• Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Recurrent Primary CNS LymphomaCompletedNCT00082836Not applicable
• Rituximab, Carmustine; Cytarabine, Etoposide, & Melphalan; Stem Cell Transplantation for Non-Hodgkin's LymphomaCompletedNCT00080886Phase 2
• FR901228 Alone or Combined With Rituximab and Fludarabine in Treating Patients With Relapsed or Refractory Low-Grade B-Cell Non-Hodgkin's LymphomaTerminatedNCT00079443Phase 2
• SDX-105 in Combination With Rituxan for Patients With Relapsed Indolent or Mantle Cell Non-Hodgkin's Lymphoma (NHL)CompletedNCT00076349Phase 2
• Study to Assess the Efficacy and Safety of Rituximab in Patients With Rheumatoid ArthritisCompletedNCT00074438Phase 2
• An Open Label Pilot Study Examining the Use of Rituximab in Patients With Wegener's Granulomatosis Who Have Experienced Disease Relapse on Standard TherapiesCompletedNCT00072592Phase 1
• Cladribine and Rituximab as Remission Induction Therapy Followed By Rituximab and Stem Cell Mobilization in Treating Patients With CLLCompletedNCT00072007Phase 2
• Rituximab, Prednisone, Cyclophosphamide, Doxorubicin, Vincristine, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Previously Untreated Mantle Cell LymphomaCompletedNCT00070447Phase 2
• Oblimersen, Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell LymphomaCompletedNCT00070083Phase 1
• Bortezomib and Fludarabine With or Without Rituximab in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma or Chronic Lymphocytic LeukemiaCompletedNCT00068315Phase 1
• Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Post-Transplant Lymphoproliferative DisorderCompletedNCT00064246Phase 1/2
• Combination Chemotherapy With or Without Rituximab in Non-Hodgkin's LymphomaCompletedNCT00064116Phase 3
• Epirubicin and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic LeukemiaCompletedNCT00062296Phase 2
• Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Non-Hodgkin's LymphomaCompletedNCT00062114Phase 2
• Dose Ranging Trial for Pixantrone in the FND-R Variant Regimen in Indolent Non-Hodgkin's LymphomaCompletedNCT00060684Phase 1
• Comparative Trial for Pixantrone in Combination With Rituximab in Indolent Non-Hodgkin's LymphomaTerminatedNCT00060671Phase 3
• Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Waldenstrom's MacroglobulinemiaTerminatedNCT00060294Phase 1
• Rituximab and Interleukin-2 in Treating Patients With Relapsed or Refractory Intermediate- or High-Grade Non-Hodgkin's LymphomaCompletedNCT00059904Phase 2
• Combination Chemotherapy and Rituximab in Treating Young Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or Acute Lymphoblastic LeukemiaTerminatedNCT00058461Phase 2
• Radiolabeled Monoclonal Antibody Therapy and High-Dose Chemotherapy Followed By Autologous Peripheral Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's LymphomaCompletedNCT00058292Phase 1
• Alvocidib, Fludarabine Phosphate, and Rituximab in Treating Patients With Lymphoproliferative Disorders or Mantle Cell LymphomaCompletedNCT00058227Phase 1
• Safety of Interferon Gamma-1b With Rituximab in Non-Hodgkin's Lymphoma PatientsTerminatedNCT00057447Phase 1/2
• Safety and Efficacy of Zevalin in the Treatment of Non-Hodgkin's LymphomaTerminatedNCT00057343Phase 3
• Combination Chemotherapy With or Without Rituximab in Treating Patients With Mantle Cell LymphomaCompletedNCT00053092Phase 2
• Rituximab and Cladribine in Treating Patients With Newly Diagnosed Non-Hodgkin's LymphomaCompletedNCT00053027Phase 2
• Combination Chemotherapy With or Without Rituximab in Treating Older Patients With Non-Hodgkin's LymphomaCompletedNCT00052936Phase 3
• Stem Cell Transplantation With or Without Rituximab in Treating Patients With Relapsed or Progressive B-Cell Diffuse Large Cell LymphomaCompletedNCT00052923Phase 3
• Rituximab to Treat Neuropathy With Anti-MAG AntibodiesCompletedNCT00050245Phase 2
• Combination Chemotherapy and Rituximab in Treating Patients With Chronic Lymphocytic Leukemia or Lymphocytic LymphomaCompletedNCT00049413Phase 2
• Proleukin in Combination With Rituxan in Patients With Low-Grade Non-Hodgkin's Lymphoma Who Have Previously Failed Rituxan TreatmentsCompletedNCT00045877Phase 2/3
• Proleukin in Combination With Rituxan in Patients With Intermediate and High-Grade Non-Hodgkin's Lymphoma.CompletedNCT00045864Phase 2
• Anti-CD20 in Systemic Lupus ErythematosusCompletedNCT00036491Phase 1/2
• Radiolabeled Monoclonal Antibody in Treating Patients With Relapsed or Refractory Non-Hodgkin's LymphomaTerminatedNCT00033423Phase 1
• Combination Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With Non-Hodgkin's LymphomaCompletedNCT00032019Phase 2
• Rituximab Plus Combination Chemotherapy in Treating Patients With HIV-Related Non-Hodgkin's LymphomaStatus unknownNCT00031902Phase 1
• Monoclonal Antibody Therapy in Relapsed Non-Hodgkin's After Chemotherapy and Autologous Stem Cell TransplantationCompletedNCT00031642Phase 1/2
• Combination Chemotherapy Plus Filgrastim With or Without Rituximab in Treating Older Patients With Non-Hodgkin's LymphomaStatus unknownNCT00028717Phase 3
• Cyclophosphamide W/or W/Out Rituximab and Peripheral Stem Cell Transplantation in Patients With Recurrent Non-Hodgkin's LymphomaCompletedNCT00028665Phase 2
• Pentostatin and Rituximab in Treating Patients With Low-Grade Non-Hodgkin's Lymphoma or Chronic Lymphocytic LeukemiaCompletedNCT00026351Phase 2
• Rituximab and Interleukin-12 in Treating Patients With B-Cell Non-Hodgkin's LymphomaCompletedNCT00026182Phase 2
• Combination Antibody Therapy for Relapsed Lymphoma and Chronic Lymphocytic LeukemiaTerminatedNCT00022971Phase 1
• Chemotherapy and Rituximab With Peripheral Stem Cell Transplantation in Treating Patients With Mantle Cell LymphomaCompletedNCT00020943Phase 2
• Rituximab Plus Fludarabine in Treating Patients With Waldenstrom's MacroglobulinemiaCompletedNCT00020800Phase 2
• Monoclonal Antibody Therapy and Peripheral Stem Cell Transplant in Treating Patients With Non-Hodgkin's LymphomaCompletedNCT00017381Early Phase 1
• Rituximab Plus Interleukin-2 in Treating Patients With Hematologic CancerCompletedNCT00010192Phase 1
• Combination Chemotherapy Plus Rituximab in Treating Patients With Recurrent or Refractory Non-Hodgkin's LymphomaCompletedNCT00007865Phase 2
• Rituximab & Combination Chemotherapy Followed by Transplantation in Relapsed or Refractory Non-Hodgkin's LymphomaCompletedNCT00007852Phase 2
• S0019 Combination Chemotherapy With or Without Rituximab in Treating Patients With Relapsed or Refractory Non-Hodgkin's LymphomaTerminatedNCT00006708Phase 3
• Rituximab Followed by Combination Chemotherapy in Treating Patients With Refractory or Recurrent Non-Hodgkin's LymphomaWithdrawnNCT00006669Phase 2
• A Study of Rituxan in the Treatment of Polyneuropathies Associated With Serum IgM AutoantibodiesStatus unknownNCT00006072Phase 2
• Combination Chemotherapy Plus Rituximab in Treating Patients With Intermediate-Grade or High-Grade Non-Hodgkin's LymphomaStatus unknownNCT00005959Phase 2
• Phase II Study of Rituximab in Patients With Immune Thrombocytopenic PurpuraCompletedNCT00005652Phase 2
• Rituximab and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Large Cell LymphomaCompletedNCT00005631Phase 2
• Rituximab in Treating Patients With Waldenstrom's MacroglobulinemiaCompletedNCT00005609Phase 2
• Combination Chemotherapy Plus Rituximab in Treating Patients With Relapsed Non-Hodgkin's LymphomaCompletedNCT00005601Phase 2
• Combination Chemotherapy Plus Peripheral Stem Cell Transplantation With or Without Rituximab in Treating Patients With Relapsed Non-Hodgkin's LymphomaCompletedNCT00005589Phase 3
• S0014 Combination Chemotherapy Plus Rituximab and Radiation Therapy in Treating Patients With Stage I or Stage II Non-Hodgkin's LymphomaCompletedNCT00005089Phase 2
• Rituximab in Treating Patients With Waldenstrom's MacroglobulinemiaCompletedNCT00004889Phase 2
• Interleukin-12 Plus Rituximab in Treating Patients With Non-Hodgkin's LymphomaCompletedNCT00004260Phase 1
• Combination Chemotherapy With or Without Rituximab in Treating Patients With Relapsed Non-Hodgkin's LymphomaCompletedNCT00004179Phase 3
• Combination Chemotherapy With or Without Rituximab in Treating Patients With Newly Diagnosed Non-Hodgkin's LymphomaCompletedNCT00004112Phase 3
• Monoclonal Antibody Therapy or Biological Therapy in Treating Patients With Chronic Lymphocytic Leukemia or Multiple Myeloma in Remission After ChemotherapyWithdrawnNCT00004040Phase 2
• Combination Chemotherapy Plus Interferon Alfa or Rituximab in Treating Patients With Stage III or Stage IV LymphomaWithdrawnNCT00004039Phase 2
• Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With B-cell Non-Hodgkin's Lymphoma That Has Relapsed Following Peripheral Stem Cell TransplantationCompletedNCT00003963Phase 2
• Rituximab in Treating Patients With Non-Hodgkin's Lymphoma or Hodgkin's DiseaseCompletedNCT00003849Phase 2
• Rituximab in Treating Patients With Refractory or Recurrent Hairy Cell Leukemia Following Cladribine TherapyCompletedNCT00003757Phase 2
• Monoclonal Antibody Therapy in Treating Patients With Lymphoproliferative Disorder Associated With Immunosuppression TherapyCompletedNCT00003716Phase 2
• Rituximab and Dexamethasone in Treating Patients With Recurrent or Refractory Indolent Non-Hodgkin's LymphomaWithdrawnNCT00003663Phase 2
• Pentostatin, Cyclophosphamide, and Rituximab in Treating Patients With Chronic Lymphocytic Leukemia or Other B-cell CancersCompletedNCT00003658Phase 2
• Rituximab Plus Cyclophosphamide in Treating Patients With Indolent Stage III or Stage IV Non-Hodgkin's LymphomaWithdrawnNCT00003605Phase 2
• Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Patients With Previously Untreated HIV-Associated Non-Hodgkin's LymphomaCompletedNCT00003595Phase 3
• Rituximab in Treating Patients With Multiple MyelomaCompletedNCT00003554Phase 2
• Peripheral Stem Cell Transplantation Plus Combination Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With Non-Hodgkin's LymphomaCompletedNCT00003397Phase 2
• Rituximab Plus Interleukin-2 in Treating Patients With LymphomaCompletedNCT00003356Phase 1/2
• Monoclonal Antibody Therapy in Treating Patients With Follicular or Mantle Cell LymphomaCompletedNCT00003280Phase 3
• Fludarabine and Monoclonal Antibody Therapy in Treating Patients With Untreated B-cell Chronic Lymphocytic LeukemiaCompletedNCT00003248Phase 2
• Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Patients With Stage III or Stage IV Low-Grade Non-Hodgkin's LymphomaCompletedNCT00003204Phase 3
• A Phase II Clinical Trial of Suppression of Human Antimouse Antibody and Human Antitoxin Response to Immunotoxin LMB-1 by RituximabCompletedNCT00001805Phase 2
• EPOCH Chemotherapy +/- IL-12 for Previously Untreated and EPOCH Plus Rituximab for Previously Treated Patients With AIDS-Associated LymphomaCompletedNCT00001563Phase 2

← Rituximab overview